pemafibrate
Kowa Pharmaceuticals
['venous thromboembolism', 'illumina']
impressively run #prominent trial with ~10k patients with dm2+high tg+low hdl-c: 20-30% reduction in tg with #pemafibrate but no reduction in cv events or death. venous thromboembolism. disappointing but illuminating nevertheless. #aha2022 
Cardiology, outcomes research, health econ | Assoc Prof @HarvardMed | Assoc Director @SmithBIDMC | CCU Director @BIDMChealth | Co-Chair, AHA International Com